In pre-clinical studies, treatment withTMA-15 up to 24 h after infection ameliorated the lethal Stx2-producingSTEC strain B2F1 challenge in mice.73 However,the urtoxazumab dosage needed to protect the STEC-infected mice appearsto be significantly higher as compared to that of cαStx2.64 The efficacy of urtoxazumab has also been evaluatedin a gnotobiotic piglet model, and the results indicate that urtoxazumabreduces post-infection neurological sequelae.74 The developmental future of urtoxazumab remains unclear. Here, STX2 is linked to infection.